Cabaletta Bio (CABA) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

CABA Cabaletta Bio

Watchlist

1.870
-0.390-17.26%

Close Nov 21 16:00 ET

1.890
+0.020+1.07%

Post 16:15 ET

91.40MMarket Cap-865P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Cabaletta Bio Reports Q3 2024 Financial Results
TipRanksNov 18 22:54 ET
Express News | Cabaletta Bio Announces Presentation Of Updated CABA-201 Clinical Data At ACR Convergence 2024l; Says Safety Profile Suggested Favorable Risk-Benefit With No CRS Or ICANS In Majority Of Patients
BenzingaNov 18 07:22 ET
Cabaletta Bio's CABA-201 Shows Results in Autoimmune Disease Trials
BenzingaNov 18 07:11 ET
William Blair Maintains Cabaletta Bio(CABA.US) With Buy Rating
Moomoo NewsNov 18 04:33 ET · Ratings
Cabaletta Bio Is Maintained at Overweight by Wells Fargo
Dow JonesNov 15 14:23 ET · Ratings
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $25
Moomoo NewsNov 15 11:32 ET · Ratings

Comments

Dps

Nov 19 14:57

$Cabaletta Bio (CABA.US)$ what happened to it

Dps

Oct 10 14:04

$Cabaletta Bio (CABA.US)$ poor stock … not growing at all

Dps

Oct 4 14:30

$Cabaletta Bio (CABA.US)$ what happened to it … no improvement at all

Jaguar8

Sep 25 15:39

NEWS

$Cabaletta Bio (CABA.US)$
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
Cabaletta Bio (Nasdaq: CABA) announced two presentations at the upcoming American College of Rheumatology (ACR) Convergence 2024, featuring new and updated clinical data on CABA-201, their 4-1BB-containing fully human CD19-CAR T cell investigational therapy. The presentations will cover:
1. An oral presentation on the safety and efficacy of C...